topotecan has been researched along with Carcinoma, Neuroendocrine in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullah, H; Agrawal, S; Deng, M; Meeker, C; Sreekrishnanilayam, K; Vijayvergia, N; Yeung, HM | 1 |
| Apostolidis, L; Bergmann, F; Jäger, D; Winkler, EC | 1 |
| Brown, J; Burzawa, JK; Byers, LA; Coleman, RL; Frumovitz, M; Munsell, MF; Ramalingam, P | 1 |
| Cassier, P; Chapet, O; Chekrine, T; De Bari, B; Kulisa, M; Mornex, F | 1 |
| Ansell, SM; Green, EM; Mahoney, MR; Rubin, J | 1 |
1 review(s) available for topotecan and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
[Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature].
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma in Situ; Carcinoma, Neuroendocrine; Carcinoma, Transitional Cell; Combined Modality Therapy; Emergencies; Etoposide; Humans; Lymphatic Irradiation; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Prognosis; Prostatic Hyperplasia; Topoisomerase I Inhibitors; Topotecan; Urinary Bladder Neoplasms | 2011 |
1 trial(s) available for topotecan and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Islet Cell; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Topotecan | 2004 |
3 other study(ies) available for topotecan and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Male; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2023 |
Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Retreatment; Tomography, X-Ray Computed; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2016 |
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Young Adult | 2017 |